UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Virginia 22313-1450 www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
10/657,725	09/08/2003	Louis C. Smith	AVSI-0010 P1 (108328.0015	8903
JACKSON WALKER LLP 901 MAIN STREET			EXAMINER	
			WILLIAMS, CATHERINE SERKE	
SUITE 6000 DALLAS, TX 75202			ART UNIT	PAPER NUMBER
			3763	<u></u>
			<u> </u>	
			MAIL DATE	DELIVERY MODE
			09/06/2007	PAPER

Please find below and/or attached an Office communication concerning this application or proceeding.

The time period for reply, if any, is set in the attached communication.

	Application No.	Applicant(s)			
	10/657,725	SMITH ET AL.			
Office Action Summary	Examiner	Art Unit			
	Catherine S. Williams	3763			
The MAILING DATE of this communication app Period for Reply	pears on the cover sheet with the c	correspondence address			
A SHORTENED STATUTORY PERIOD FOR REPLY WHICHEVER IS LONGER, FROM THE MAILING DA - Extensions of time may be available under the provisions of 37 CFR 1.13 after SIX (6) MONTHS from the mailing date of this communication. - If NO period for reply is specified above, the maximum statutory period v - Failure to reply within the set or extended period for reply will, by statute. Any reply received by the Office later than three months after the mailing earned patent term adjustment. See 37 CFR 1.704(b).	ATE OF THIS COMMUNICATION 36(a). In no event, however, may a reply be tin will apply and will expire SIX (6) MONTHS from , cause the application to become ABANDONE	N. nely filed the mailing date of this communication. D (35 U.S.C. § 133).			
Status					
1) Responsive to communication(s) filed on 15 Ju	une 2007.				
2a)⊠ This action is FINAL . 2b)☐ This	This action is FINAL . 2b) ☐ This action is non-final.				
,					
closed in accordance with the practice under E	Ex parte Quayle, 1935 C.D. 11, 4	53 O.G. 213.			
Disposition of Claims					
4) ⊠ Claim(s) 1-27 is/are pending in the application. 4a) Of the above claim(s) 20-26 is/are withdraw 5) □ Claim(s) is/are allowed. 6) ⊠ Claim(s) 1-19 and 27 is/are rejected. 7) □ Claim(s) is/are objected to. 8) □ Claim(s) are subject to restriction and/o	vn from consideration.				
Application Papers	I				
9) The specification is objected to by the Examine 10) The drawing(s) filed on is/are: a) acc Applicant may not request that any objection to the Replacement drawing sheet(s) including the correct 11) The oath or declaration is objected to by the Ex	epted or b) objected to by the drawing(s) be held in abeyance. Se tion is required if the drawing(s) is ob	e 37 CFR 1.85(a). ejected to. See 37 CFR 1.121(d).			
Priority under 35 U.S.C. § 119					
 12) Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f). a) All b) Some * c) None of: Certified copies of the priority documents have been received. Certified copies of the priority documents have been received in Application No Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)). * See the attached detailed Office action for a list of the certified copies not received. 					
Attachment(s) 1) Notice of References Cited (PTO-892) 2) Notice of Draftsperson's Patent Drawing Review (PTO-948) 3) Information Disclosure Statement(s) (PTO/SB/08) Paper No(s)/Mail Date	4) Interview Summary Paper No(s)/Mail D 5) Notice of Informal F 6) Other:	ate			

Art Unit: 3763

DETAILED ACTION

Claim Rejections - 35 USC § 102

The following is a quotation of the appropriate paragraphs of 35 U.S.C. 102 that form the basis for the rejections under this section made in this Office action:

A person shall be entitled to a patent unless -

(e) the invention was described in (1) an application for patent, published under section 122(b), by another filed in the United States before the invention by the applicant for patent or (2) a patent granted on an application for patent by another filed in the United States before the invention by the applicant for patent, except that an international application filed under the treaty defined in section 351(a) shall have the effects for purposes of this subsection of an application filed in the United States only if the international application designated the United States and was published under Article 21(2) of such treaty in the English language.

Claims 1-7,11-13 and 18-19 are rejected under 35 U.S.C. 102(e) as being anticipated by Rubinsky et al (USPN 6,387,671). Rubinsky discloses an electrode assembly having a plurality of needle electrodes; a current waveform generator; a power source and a controller. See figure 7; 4:38-57; 10:44-45,52; 11:20-36; 13:45-63; and 14:26-34,59-63.

Claim Rejections - 35 USC § 103

The following is a quotation of 35 U.S.C. 103(a) which forms the basis for all obviousness rejections set forth in this Office action:

(a) A patent may not be obtained though the invention is not identically disclosed or described as set forth in section 102 of this title, if the differences between the subject matter sought to be patented and the prior art are such that the subject matter as a whole would have been obvious at the time the invention was made to a person having ordinary skill in the art to which said subject matter pertains. Patentability shall not be negatived by the manner in which the invention was made.

Claims 8-10 are rejected under 35 U.S.C. 103(a) as being unpatentable over Rubinsky.

Rubinsky meets the claim limitations as described above but fails to disclose a communications port specifically an optical serial port or an infrared port. However, wireless communication is

Art Unit: 3763

well known in the medical device art in general and is provided in order to make use of the device easier for the patient and medical technician.

At the time of the invention, it would have been obvious to incorporate an optical serial port or an IR port into the invention of Rubinsky. These devices are well known in the art and the motivation for the incorporation would have been known generally by one skilled in the art. The incorporation would have been done in order to make the use of the device easier for the patient and medical technician thereby enhancing the device in general.

Claims 14-15 are rejected under 35 U.S.C. 103(a) as being unpatentable over Rubinsky in view of Hofmann (USPN 5,318,514). Rubinsky meets the claim limitations as described above but fails to disclose that the electrode assembly has a handle with a mounting structure and an activation switch. Hofmann clearly discloses a handle (24) with a mounting structure (see figure 3) and an activation switch (34).

At the time of the invention it would have been obvious to incorporate the handle of Hofman into the invention of Rubinasky. Rubinsky fails to disclose a specific structure for the needle electode assembly. The motivation for the incorporation of the handle of Hofmann into the invention of Rubinsky would have been done in order to carry out the device and method as taught by Rubinsky.

Claims 16-17 are rejected under 35 U.S.C. 103(a) as being unpatentable over Rubinsky in view of Hofmann. Rubinsky in view of Hofmann meets the claim limitations as described above

Application/Control Number: 10/657,725

Art Unit: 3763

but fails to include a LED on the handle. LEDs are well known in the medical device art as status indicators that indicate to the medical technician if a device is powered on or off.

At the time of the invention, it would have been obvious by one skilled in the art to incorporate an LED into the handle. The motivation for the incorporation would have been done in order to make the device easier to use for the medical technician.

Claim 27 is rejected under 35 U.S.C. 103(a) as being unpatentable over Rubinsky in view of Hofmann et al (USPN 5,702,359). Rubinsky meets the claim limitations as described above (see claim 1) but fails to disclose that the plurality of needle electrodes have a central channel. However, Hofmann discloses such a configuration with at least some of the needles having lumens for drug delivery. Hofmann discloses that this configuration is for enhanced performance of the device.

At the time of the invention, it would have been obvious by one skilled in the art to use the electrode array of Hofmann in the device of Rubinsky. Rubinsky fails to disclose a specific structure for the needle electode assembly. The motivation for the incorporation of the electrode assembly of Hofmann into the invention of Rubinsky would have been done in order to carry out the device and method as taught by Rubinsky with the enhanced design of Hofmann.

Response to Arguments

Applicant's arguments filed 6/15/07 have been fully considered but they are not persuasive. Applicant argues that Rubinsky does not teach the application of electrical energy effective to expose adjacent tissue to a substantially constant electrical current. However,

attention is drawn to column 11 lines 24-27 of the disclose of Rubinsky which teaches that constant current may be administered. These lines were cited in the previous office action.

Conclusion

THIS ACTION IS MADE FINAL. Applicant is reminded of the extension of time policy as set forth in 37 CFR 1.136(a).

A shortened statutory period for reply to this final action is set to expire THREE MONTHS from the mailing date of this action. In the event a first reply is filed within TWO MONTHS of the mailing date of this final action and the advisory action is not mailed until after the end of the THREE-MONTH shortened statutory period, then the shortened statutory period will expire on the date the advisory action is mailed, and any extension fee pursuant to 37 CFR 1.136(a) will be calculated from the mailing date of the advisory action. In no event, however, will the statutory period for reply expire later than SIX MONTHS from the mailing date of this final action.

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Catherine S. Williams whose telephone number is 571/2724970. The examiner can normally be reached on Monday - Friday.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Nicholas D. Lucchesi can be reached on 571/2724977. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.

Application/Control Number: 10/657,725 Page 6

Art Unit: 3763

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see http://pair-direct.uspto.gov. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative or access to the automated information system, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000.

/Catherine S. Williams/
Catherine S. Williams
Primary Examiner AU 3763
September 4, 2007